Delving into the Latest Updates on JT-3002 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

Target-

Action

stimulants

Mechanism

Immunostimulants, Macrophages stimulants

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

The present study was undertaken to investigate the effect of JT3002, a new synthetic analogue of a lipoprotein from the outer wall of a gram-negative bacterium on the production of cytokines by mouse peritoneal macrophages. Multilamellar liposomes containing different concentrations of JT3002 induced production of the inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 alpha, and interleukin-6 by macrophages in dose- and time-dependent manners. The presence of interferon-gamma enhanced production of tumor necrosis factor-alpha by macrophages exposed to lower concentrations of JT3002 and induced the release of nitric oxide, a potent cytolytic molecule of activated macrophages. Unlike lipopolysaccharide, JT3002 activated macrophages independently of serum, but like lipopolysaccharide, it required protein tyrosine kinase.

100 Deals associated with JT-3002

Login to view more data